Sort
10,766 grants matching “checkpoint inhibitor”
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
$349,700Sarat Chandarlapaty · Sloan-Kettering Inst Can Research · P50 · FY2020 · CA
Pathways of Immune Evasion in Acute Myeloid Leukemia
$349,640Evan Ferguson Lind · Oregon Health & Science University · R01 · FY2022 · CA
Pathways of Immune Evasion in Acute Myeloid Leukemia
$349,640Evan Ferguson Lind · Oregon Health & Science University · R01 · FY2025 · CA
Core B: Biospecimen Repository and Processing Core
$349,563Begonya Comin-Anduix · University Of California Los Angeles · P01 · FY2021 · CA
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance
$349,523Aimee L Edinger · University Of California-Irvine · R01 · FY2021 · CA
Targeting EphB4-ephrinB2 to decrease immunosuppression in HNSCC
$349,503Sana D Karam · University Of Colorado Denver · P50 · FY2021 · CA
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity
$349,385David C Linehan · University Of Rochester · R01 · FY2019 · CA
Immune Checkpoint Inhibition and humoral immune response in systemic autoimmunity
$349,379Hu Zeng · Mayo Clinic Rochester · R01 · FY2021 · AR
Immune Checkpoint Inhibition and humoral immune response in systemic autoimmunity
$349,379Hu Zeng · Mayo Clinic Rochester · R01 · FY2023 · AR
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism
$349,240Roderick O'Sullivan · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · CA
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism
$349,164Roderick O'Sullivan · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA
Epigenetically Engineered Mouse Model for Lung Cancer Therapy
$349,064Lanlan Shen · Baylor College Of Medicine · R01 · FY2022 · CA
Translation of commensal bacteria mechanism for immunotherapy
$349,038Howard C Hang · Scripps Research Institute, The · R01 · FY2021 · CA
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism
$349,004Roderick O'Sullivan · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · CA
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance
$348,993Aimee L Edinger · University Of California-Irvine · R01 · FY2020 · CA
Manipulation of Tumor Specific Immunity
$348,950Hans Schreiber · University Of Chicago · R01 · FY2020 · CA
Project 1: Targeting Metabolic Vulnerabilities in Lung Cancer
$348,931Ralph J Deberardinis · Ut Southwestern Medical Center · P50 · FY2020 · CA
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity
$348,892Taslim A Al-Hilal · University Of Texas El Paso · R01 · FY2022 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2020 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2022 · CA
Role of RON kinase in anti-tumor immune responses
$348,844Alana L Welm · University Of Utah · R01 · FY2018 · CA
Role of RON kinase in anti-tumor immune responses
$348,844Alana L Welm · University Of Utah · R01 · FY2021 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2018 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2020 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2017 · CA